FDA Approves First Essential Thrombocythemia Drug in Nearly Three Decades

The U.S. Food and Drug Administration (FDA) has approved ropeginterferon alfa-2b-njft (Besremi) for adults with essential thrombocythemia (ET), marking the first new approval for this rare blood cancer in almost 30 years. The decision was based on results from the SURPASS ET clinical trial.